These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 22550279

  • 1. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G.
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [Abstract] [Full Text] [Related]

  • 2. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
    Jing Y, Kalsekar I, Curkendall SM, Carls GS, Bagalman E, Forbes RA, Hebden T, Thase ME.
    Clin Ther; 2011 Sep; 33(9):1246-57. PubMed ID: 21840058
    [Abstract] [Full Text] [Related]

  • 3. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L.
    Postgrad Med; 2010 Jul; 122(4):39-48. PubMed ID: 20675970
    [Abstract] [Full Text] [Related]

  • 4. Using antipsychotic agents in older patients.
    Alexopoulos GS, Streim J, Carpenter D, Docherty JP, Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.
    J Clin Psychiatry; 2004 Jul; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [Abstract] [Full Text] [Related]

  • 5. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y, Kim E, You M, Pikalov A, Tran QV.
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY.
    J Clin Psychiatry; 2014 Sep; 75(9):e924-31. PubMed ID: 25295435
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M, Yu J, Kamat SA, Hartry A, Legacy S, Duffy R, Aigbogun MS.
    J Affect Disord; 2017 Jan 01; 207():54-62. PubMed ID: 27693466
    [Abstract] [Full Text] [Related]

  • 8. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ, Botteman MF, Schaefer K, Sarocco P, Barry N, Pickard AS.
    J Ment Health Policy Econ; 2010 Mar 01; 13(1):27-35. PubMed ID: 20571180
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A, Vardeva K, Loze JY, L'italien GJ, Sennfalt K, Baardewijk Mv.
    Curr Med Res Opin; 2008 Nov 01; 24(11):3275-85. PubMed ID: 18947458
    [Abstract] [Full Text] [Related]

  • 10. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008121. PubMed ID: 21154393
    [Abstract] [Full Text] [Related]

  • 11. The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model.
    Leelahanaj T.
    J Med Assoc Thai; 2010 Nov 08; 93 Suppl 6():S43-50. PubMed ID: 21284136
    [Abstract] [Full Text] [Related]

  • 12. The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Boulton DW, Balch AH, Royzman K, Patel CG, Berman RM, Mallikaarjun S, Reeves RA.
    J Psychopharmacol; 2010 Apr 08; 24(4):537-46. PubMed ID: 18832427
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
    Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valentí M, Vieta E.
    Int J Neuropsychopharmacol; 2010 Feb 08; 13(1):5-14. PubMed ID: 19638254
    [Abstract] [Full Text] [Related]

  • 14. Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
    Chen J, Gao K, Kemp DE.
    Curr Opin Psychiatry; 2011 Jan 08; 24(1):10-7. PubMed ID: 21088586
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.
    Woodward TC, Tafesse E, Quon P, Lazarus A.
    Pharmacoeconomics; 2010 Jan 08; 28(9):751-64. PubMed ID: 20623994
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K, Hassan M, O'Day K, Meyer K, Grossman F.
    J Med Econ; 2013 Jul 08; 16(7):951-61. PubMed ID: 23701260
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.
    J Clin Psychopharmacol; 2008 Apr 08; 28(2):156-65. PubMed ID: 18344725
    [Abstract] [Full Text] [Related]

  • 18. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.
    J Clin Psychiatry; 2008 Dec 08; 69(12):1928-36. PubMed ID: 19192475
    [Abstract] [Full Text] [Related]

  • 19. Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
    Jing Y, Guo Z, Kalsekar I, Forbes RA, Hebden T, Thase ME.
    Int Clin Psychopharmacol; 2013 Mar 08; 28(2):87-90. PubMed ID: 23262644
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.